Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2026-05-27 Investor Presentation
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Please find enclosed Investor Presentation on Q4 & FY26 Results
Investor Presentation Classification · 93% confidence The document is addressed to stock exchanges and is titled “Investor Presentation – Q4 & FY26.” It contains slide content, strategic updates, financial highlights, charts, and forward-looking statements typical of a presentation to investors rather than an earnings press release or regulatory notice. It is well over 5,000 characters and contains the full presentation itself. Therefore, it is classified as an Investor Presentation.
2026-05-27 English
Please find enclosed press release
Earnings Release Classification · 90% confidence The document is a press release filed with stock exchanges summarizing key Q4 FY26 financial results (net profit, revenue growth) and other highlights (EBITDA, business updates, dividend proposal). It does not contain full financial statements or a detailed interim report structure; rather, it is the initial announcement of quarterly results. Therefore, it fits the definition of an Earnings Release. Q4 2026
2026-05-27 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release sent to the stock exchanges announcing Morepen Laboratories’ Q4 FY26 financial results – key metrics like revenue, net profit growth, business highlights, and a board‐proposed dividend. It is not a full quarterly report with detailed financial statements, nor just a regulatory notice; it is an initial earnings announcement. Therefore it best fits the Earnings Release category. Q4 2026
2026-05-27 English
Investor Presentation
Investor Presentation Classification · 98% confidence The document is titled “Investor Presentation – Q4 & FY26” and contains slide-style content (strategic overview, financial highlights, charts, graphs, and forward-looking statements). It is clearly a full investor presentation delivered to stock exchanges, not merely an announcement or brief summary. This matches the Investor Presentation category.
2026-05-27 English
Re-appointment of Cost Auditors of the Company
Regulatory Filings Classification · 65% confidence The document is a formal SEBI‐mandated disclosure to stock exchanges detailing the outcome of the Board of Directors meeting (approval of business transfer agreement addendum, approval of audited results, dividend recommendation, auditor reappointment) along with the declaration under Regulation 33 and the independent auditor’s report. It is not a full annual report (10-K), nor is it simply an earnings highlights press release (ER), interim report (IR) or management change notice (MANG). It is a regulatory compliance filing under India’s Listing Obligations and Disclosure Requirements that does not neatly fit another specific category, making Regulatory Filings (RNS) the appropriate classification.
2026-05-26 English
Please find attached the file
Earnings Release Classification · 75% confidence The document is a formal stock-exchange filing under SEBI Listing Regulations reporting the outcome of a Board meeting, which includes the approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. This constitutes the company’s earnings release rather than a full annual report or an interim/quarterly report document. It is not merely a certification or publication notice but the actual announcement of financial results. Hence it best fits the Earnings Release category (ER). FY 2026
2026-05-26 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.